All In Biotech

Drug Trial Radar · NCT07607964

A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 in Adult Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)

A Phase 1, First-in-Human, Single Ascending Dose, Open-label, Non-randomized Study Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of ABBV-519 in Subjects With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)

Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

May 28, 2026

Primary completion

Jan 2029

Study completion Jan 2029

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
May 27, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Systemic lupus erythematosus (SLE) is a chronic, systemic autoimmune disease characterized by B cell hyperactivity. Rheumatoid Arthritis (RA) is a chronic inflammatory disease causing pain, stiffness, swelling and loss of joint function. The purpose of this study is to assess the pharmacokinetics, pharmacodynamics and safety of ABBV-519 in adult participants with SLE or RA. This is a single ascending dose study in an estimated 30 adult participants with moderate SLE or RA. The total duration of the study will be approximately 425 days (60-day Screening Period, 1-day Treatment Period, and a 52 week Follow-up Period) at approximately 15 to 20 sites globally. There may be higher treatment burden for participants in this trial compared to their standard of care (due to study procedures). Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Conditions

  • Systemic Lupus Erythematosus
  • Rheumatoid Arthritis

Interventions

  • ABBV-519Drug

    Intravenous (IV) Infusion

  • ABBV-519Drug

    Subcutaneous (SC) Injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline in B Cells in BloodTime frame: Up to 365 Days
  2. Maximum Plasma Concentration (Cmax) of ABBV-519.Time frame: Up to 85 Days
  3. Time to Cmax (Tmax) of ABBV-519Time frame: Up to 85 Days
  4. Terminal Phase Elimination Half-Life (t1/2) of ABBV-519Time frame: Up to 85 Days
  5. Area Under the Concentration-Time Curve From Time 0 to Last Measurable Concentration (AUCt) of ABBV-519Time frame: Up to 85 Days
  6. Percentage of Participants with Detection of Anti-Drug Antibodies (ADAs) for ABBV-519Time frame: Up to 169 Days
  7. Number of Participants with Adverse Events (AEs)Time frame: Up to 425 Days

Locations

17 sites in 2 countries. Site status is shown where the registry gives one.

  • Pinnacle Research Group /ID# 278677

    Anniston, Alabama · Recruiting

  • Solace Research /ID# 279155

    Tustin, California · Recruiting

  • Clinical Research Of West Florida - Phase I Unit /ID# 279292

    Clearwater, Florida · Recruiting

  • Finlay Medical Research - Greenacres /ID# 278380

    Greenacres City, Florida · Recruiting

  • Clinical Research of Osceola /ID# 278374

    Kissimmee, Florida · Recruiting

  • Allied Biomedical Research Institute /ID# 284408

    Miami, Florida · Recruiting

  • Discovery Health Research Center /ID# 279691

    Plantation, Florida · Recruiting

  • Clinical Research Of West Florida - Tampa - North Howard Avenue /ID# 279130

    Tampa, Florida · Recruiting

  • Advanced Quality Medical Research /ID# 279147

    Orland Park, Illinois · Recruiting

  • West Tennessee Research Institute - Jackson /ID# 284561

    Jackson, Tennessee · Recruiting

  • Accurate Clinical Research - Houston /ID# 278382

    Houston, Texas · Recruiting

  • Epic Medical Research /ID# 279180

    Red Oak, Texas · Recruiting

  • Japan Community Healthcare Organization Chukyo Hospital /ID# 279611

    Nagoya, Aichi-ken, Japan · Recruiting

  • Okayama University Hospital /ID# 279763

    Okayama, Okayama-ken, Japan · Recruiting

  • Institute of Science Tokyo Hospital /ID# 279648

    Bunkyo-ku, Tokyo, Japan · Recruiting

  • Keio University Hospital /ID# 280003

    Shinjuku-ku, Tokyo, Japan · Recruiting

  • National Center for Global Health and Medicine /ID# 281191

    Shinjuku-ku, Tokyo, Japan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.